In Hyderabad, India, a major pharmaceutical manufacturing hub operates around the clock producing more than 100 generic medications, including antihistamines, statins, and antidepressants. The facility, run by Dr. Reddy’s Laboratories, employs approximately 1,900 workers who manufacture nearly one billion oral doses monthly. About 75 percent of these drugs are supplied to patients in the United States, underscoring India’s central role in the global generic drug market.

India’s pharmaceutical industry has become a cornerstone of worldwide drug supply due in large part to its combination of affordable labor and decades of technical expertise. The country’s generics are produced at a fraction of the cost compared to American manufacturing, creating a significant competitive advantage. This has presented challenges for efforts within the United States to bring drug production back domestically.

Under the Trump administration, proposals to impose tariffs on generic drugs surfaced as a strategy to encourage pharmaceutical companies to relocate manufacturing to the U.S. In July, former President Trump announced plans to implement a 100 percent tariff on imported generic drugs in 2028, increasing to 200 percent the following year. However, the U.S. recently enacted a 100 percent tariff on certain pharmaceutical imports but notably exempted generic drugs, amid concerns from healthcare professionals that tariffs could increase costs, trigger rationing, and cause shortages.

Despite potential tariffs, industry experts argue that India’s cost advantage may be difficult to overcome. Sudarshan Jain, secretary general of the Indian Pharmaceutical Alliance, estimates that producing the same tablets and liquids in the U.S. would cost at least four times more than in India. This price gap is rooted not only in labor costs, which are markedly lower in India, but also in faster factory setup times and more efficient manufacturing processes.

India’s journey in generics began in the 1970s, focusing on affordable medications for its large population while Western pharmaceutical companies prioritized patent protections. Until 2005, India did not recognize drug patents, which allowed domestic firms to develop reverse-engineered versions of complex drugs. Since aligning its patent laws with World Trade Organization standards, Indian manufacturers have expanded to supply generic medications across Asia, Africa, Latin America, and increasingly, the United States, where generics now make up 90 percent of prescriptions.

While India’s generics industry has faced quality control challenges in the past, including high-profile scandals in the early 2000s, recent efforts have improved standards. Dr. Reddy’s reports compliance with surprise inspections, and Piramal Global Pharma, another major manufacturer with facilities across India, Europe, and the U.S., has passed numerous regulatory audits without significant violations.

Piramal’s business includes contract manufacturing for patented drugs, with a geographically distributed supply chain that highlights the complexity of pharmaceutical production. Some drug components travel internationally, such as shipments moving between India, Singapore, and the United States before reaching patients, making a strict national production model difficult to implement.

Further complicating the issue, India remains reliant on China for active pharmaceutical ingredients—a critical component of drug manufacturing. Industry leaders suggest greater cooperation between India and the U.S. could strengthen supply chains and reduce dependence on China, rather than isolate their pharmaceutical industries through tariffs and production reshoring efforts.

This interconnected landscape raises key questions about the goals of bringing drug manufacturing back to the United States, whether prioritizing job creation, supply security, or cost control, and highlights the complexity of pharmaceutical globalization in the 21st century.